Version 1
: Received: 25 September 2024 / Approved: 26 September 2024 / Online: 26 September 2024 (11:33:49 CEST)
How to cite:
Bertrand, N.; Mougel, R.; Riley, G.; Bruand, M.; GAUCHOTTE, G.; Agopiantz, M. Neurotensin and Its Involvement in Female Hormone-Sensitive Cancers. Preprints2024, 2024092086. https://doi.org/10.20944/preprints202409.2086.v1
Bertrand, N.; Mougel, R.; Riley, G.; Bruand, M.; GAUCHOTTE, G.; Agopiantz, M. Neurotensin and Its Involvement in Female Hormone-Sensitive Cancers. Preprints 2024, 2024092086. https://doi.org/10.20944/preprints202409.2086.v1
Bertrand, N.; Mougel, R.; Riley, G.; Bruand, M.; GAUCHOTTE, G.; Agopiantz, M. Neurotensin and Its Involvement in Female Hormone-Sensitive Cancers. Preprints2024, 2024092086. https://doi.org/10.20944/preprints202409.2086.v1
APA Style
Bertrand, N., Mougel, R., Riley, G., Bruand, M., GAUCHOTTE, G., & Agopiantz, M. (2024). Neurotensin and Its Involvement in Female Hormone-Sensitive Cancers. Preprints. https://doi.org/10.20944/preprints202409.2086.v1
Chicago/Turabian Style
Bertrand, N., Guillaume GAUCHOTTE and Mikaël Agopiantz. 2024 "Neurotensin and Its Involvement in Female Hormone-Sensitive Cancers" Preprints. https://doi.org/10.20944/preprints202409.2086.v1
Abstract
Neurotensin (NT) is a peptide involved in digestion, neuromodulation, and cancer progression. NT and its receptors (NTR1 and SORT1 mainly) have been widely studied in oncology. Data show NT expression is under the control of sex steroid hormones, in particular estradiol. We focused on its involvement in three main female hormone-sensitive cancers: breast, ovarian, and endometrial cancer in a narrative review. NT, NTR1 and SORT1 are mostly expressed in these three cancers and their involvement in oncologic processes such as proliferation and invasion seems to match, as does their impact on prognosis for most. The development of NT receptor-targeted therapies, including theranostics and radioligand treatments, presents a promising avenue for personalized cancer treatment.
Keywords
neurotensin; breast cancer; ovarian cancer; endometrial cancer
Subject
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.